Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SLC29A1 | Q99808 | 6/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20164652 | 0.80 | SLC29A1 (0.44) | HTTSLC29A1KMT2APOLBKDM4E | |
| SCHEMBL20164364 | 0.78 | SLC29A1 (0.51) | SLC29A1KMT2APOLBKDM4EMAPK1 | |
| SCHEMBL20164638 | 0.78 | SLC29A1 (0.54) | HTTSLC29A1KMT2APOLBKDM4E | |
| SCHEMBL20164431 | 0.78 | SLC29A1 (0.46) | HTTSLC29A1KMT2APOLBKDM4E | |
| SCHEMBL20164550 | 0.77 | HTT (0.40) | HTTSLC29A1KMT2APOLBKDM4E | |
| SCHEMBL20164316 | 0.77 | CCNE1 (0.31) | SLC29A1 | |
| Hydrochloric Acid SCHEMBL20164786 | 0.77 | SLC29A1 (0.50) | HTTSLC29A1KMT2APOLBKDM4E | |
| SCHEMBL20164636 | 0.74 | SLC29A1 (0.43) | HTTSLC29A1KMT2APOLBKDM4E | |
| SCHEMBL20164700 | 0.74 | HTT (0.49) | HTTSLC29A1KMT2APOLBKDM4E | |
| SCHEMBL7937474 | 0.73 | SLC29A1 (0.35) | SLC29A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3316890-B1 | NOVEL BREATHING CONTROL MODULATING COMPOUNDS, AND METHODS OF MAKING AND USING SAME | NEURAD LTD (IL) | 2023-09-06 | — | — | EP | disclosed |
| US-10294228-B2 | Breathing control modulating compounds, and methods of making and using same | NEURAD LTD. (IL) | 2019-05-21 | — | — | US | disclosed |
| US-20180141953-A1 | Novel Breathing Control Modulating Compounds, and Methods of Making and Using Same | NEURAD LTD. (IL) | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180141953-A1 | Novel Breathing Control Modulating Compounds, and Methods of Making and Using Same | MTNR1B, CHRM3, PER2 | HTT 1972/4885SLC29A1 4472/4885KMT2A 2456/4885 |
| US-10294228-B2 | Breathing control modulating compounds, and methods of making and using same | MTNR1B, PDE3A, CHRM3 | HTT 1791/4885SLC29A1 4518/4885KMT2A 2528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.